PDCD1LG2 and triple-negative breast carcinoma: In humans, immunotherapy using monoclonal antibodies targeting the PD-1/PD-L1/PD-L2 axis has revolutionized the treatment of malignant neoplasms, including metastatic triple-negative breast cancer, with astonishing results.